Cantaluppi Vincenzo, Medica Davide, Mannari Claudio, Stiaccini Giulia, Figliolini Federico, Dellepiane Sergio, Quercia Alessandro Domenico, Migliori Massimiliano, Panichi Vincenzo, Giovannini Luca, Bruno Stefania, Tetta Ciro, Biancone Luigi, Camussi Giovanni
Nephrology, Dialysis and Kidney Transplantation Unit and Center for Experimental Medical Research (CeRMS), Department of Medical Sciences, University of Torino, Torino, Italy.
Department of Pharmacology, University of Pisa, Pisa, Italy.
Nephrol Dial Transplant. 2015 Mar;30(3):410-22. doi: 10.1093/ndt/gfu364. Epub 2014 Dec 8.
Endothelial progenitor cells (EPCs) are known to induce tissue repair by paracrine mechanisms including the release of growth factors and extracellular vesicles (EVs), nanoparticles able to carry proteins and genetic information to target cells. The aim of this study was to evaluate whether EVs derived from EPCs may protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis.
EVs were isolated by serial ultracentrifugation from supernatants of cultured human EPCs and characterized for their protein and RNA content. In vivo, EVs were injected i.v. in the experimental rat model of mesangiolytic anti-Thy1.1 glomerulonephritis evaluating renal function, proteinuria, complement activity and histological lesions. In vitro, the biological effects of EPC-derived EVs were studied in cultured rat mesangial cells incubated with anti-Thy1.1 antibody and rat or human serum as complement source.
After i.v. injection in Thy1.1-treated rats, EVs localized within injured glomeruli and inhibited mesangial cell activation, leucocyte infiltration and apoptosis, decreased proteinuria, increased serum complement haemolytic activity (CH50) and ameliorated renal function. EV treatment decreased intraglomerular deposition of the membrane attack complex (MAC or C5b-9) and expression of smooth muscle cell actin and preserved the endothelial antigen RECA-1 and the podocyte marker synaptopodin. The protective effect of EVs was significantly reduced by pre-treatment with a high dose of RNase (1 U/mL), suggesting a key role for EV-carried RNAs in these mechanisms. Indeed, EPC-derived EVs contained different mRNAs coding for several anti-apoptotic molecules and for the complement inhibitors Factor H, CD55 and CD59 and the related proteins. The in vitro experiments aimed to investigate the mechanisms of EV protection indicated that EVs transferred to mesangial cell mRNAs coding for Factor H, CD55 and CD59 and inhibited anti-Thy1.1 antibody/complement-induced apoptosis and C5b-9/C3 mesangial cell deposition.
EVs derived from EPCs exert a protective effect in Thy1.1 glomerulonephritis by inhibition of antibody- and complement-mediated injury of mesangial cells.
已知内皮祖细胞(EPCs)通过旁分泌机制诱导组织修复,包括释放生长因子和细胞外囊泡(EVs),即能够将蛋白质和遗传信息传递给靶细胞的纳米颗粒。本研究的目的是评估EPCs来源的EVs是否能在实验性抗Thy1.1肾小球肾炎中保护免受补体介导的系膜损伤。
通过连续超速离心从培养的人EPCs上清液中分离出EVs,并对其蛋白质和RNA含量进行表征。在体内,将EVs静脉注射到系膜溶解型抗Thy1.1肾小球肾炎的实验大鼠模型中,评估肾功能、蛋白尿、补体活性和组织学损伤。在体外,在与抗Thy1.1抗体和大鼠或人血清作为补体来源孵育的培养大鼠系膜细胞中研究EPCs来源的EVs的生物学效应。
在静脉注射到经Thy1.1处理的大鼠后,EVs定位于受损肾小球内,抑制系膜细胞活化、白细胞浸润和凋亡,减少蛋白尿,增加血清补体溶血活性(CH50)并改善肾功能。EV治疗减少了膜攻击复合物(MAC或C5b - 9)在肾小球内的沉积以及平滑肌肌动蛋白的表达,并保留了内皮抗原RECA - 1和足细胞标志物突触素。用高剂量的核糖核酸酶(1 U/mL)预处理可显著降低EVs的保护作用,表明EV携带的RNA在这些机制中起关键作用。事实上,EPCs来源的EVs含有编码几种抗凋亡分子以及补体抑制剂H因子、CD55和CD59及相关蛋白的不同mRNA。旨在研究EV保护机制的体外实验表明,EVs将编码H因子、CD55和CD59的mRNA转移至系膜细胞,并抑制抗Thy1.1抗体/补体诱导的凋亡以及C5b - 9/C3在系膜细胞中的沉积。
EPCs来源的EVs通过抑制抗体和补体介导的系膜细胞损伤,在Thy1.1肾小球肾炎中发挥保护作用。